Nine patients in the first‐line treatment group and 31 in the second‐ or later‐line treatment group received EGFR‐TKIs prior to the ICI regimen, and none of them developed ILD induced by EGFR‐TKIs. Here, EGFR is linked to interstitial lung disease.